医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Upside Biotechnologies to Work with US Army on Engineered Skin Replacement

2017年05月24日 AM04:00
このエントリーをはてなブックマークに追加


 

AUCKLAND, New Zealand

Regenerative medicine start-up Upside Biotechnologies has signed a CRADA (Cooperative Research and Development Agreement) with the US Army Medical Research and Materiel Command (USAMRMC) based in Fort Detrick, Maryland.

The CRADA initiates a collaboration on both the scientific and regulatory aspects of Upside’s engineered skin product development.

New Zealand-based Upside is developing an advanced, world-class skin replacement treatment for patients suffering major burns.

Upside CEO Dr Robert Feldman says the USAMRMC has an unparalleled depth of experience in the development and treatment of major burns.

“This US Army input will be hugely valuable to Upside and will fully assist us in successfully progressing our product to the benefit of all burn sufferers, including US warriors,” Dr Feldman says.

The USAMRMC is pleased to provide guidance to Upside Biotechnologies as it navigates the US FDA approval process for a novel skin replacement product,” says Susan Taylor, product manager for the Tissue Injury and Regenerative Medicine Project Management Office at the US Army Medical Materiel Development Activity, USAMRMC.

“This product may provide a critical solution in the treatment of service members who have sustained severe burns. Our goal is to help Upside move this product as quickly and as safely as possible through the regulatory process, so it is available to our wounded service members.”

About Upside Biotechnologies

This regenerative medicine company’s technology enables a small sample of unburnt patient skin to be grown in the laboratory into large areas of full thickness skin. This lab-grown skin can be used as skin grafts in patients with major burns who do not have enough uninjured skin to provide conventional skin grafts. Upside skin is produced faster than any competitive product in development. It is supplied in larger sheets with handling characteristics preferred by burns surgeons.

The company recently announced it had raised $2.3m in its Series A funding round.

About MRMC

The US Army Medical Research and Materiel Command is the Army’s medical materiel developer, with responsibility for medical research, development, and acquisition and medical logistics management. The USAMRMC’s expertise in these critical areas helps establish and maintain the capabilities the Army needs to fight and win on the battlefield. The Command is headquartered at Fort Detrick.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170523005649/en/

CONTACT

Media contact:
Upside Biotechnologies
Dr Robert
Feldman, +64 21 246 0485
CEO
info@upside.nz
www.upside.nz

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Samsung Bioepis’ Imraldi® (Adalimumab) Recommended for Approval by European Medicines Agency
  • BionextがBiosightを市場投入:医薬品研究に革命をもたらすオンラインプラットフォーム
  • Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting
  • 2017世界移动大会-上海参展商概况
  • 新研究比较Masimo下一代SedLine®患者状态指数(PSi)与原初Psi在麻醉期间的性能